Skip to main content

Table 2 Baseline characteristics and CMR results

From: Probing the intravascular and interstitial compartments of remodeled myocardium in heart failure patients with preserved and reduced ejection fraction: a CMR study

Variable

Volunteer Gadofesveset

(n = 10)

Volunteer Gadobutrol

(n = 10)

HFpEF

Patients

(n = 6)

Post-MI

Patients

(n = 6)

Overall

p-value

Agea

35 ± 15

36 ± 11

69 ± 10

58 ± 13

< 0.001

BMI

23 ± 1

24 ± 3

26 ± 3

27 ± 3

0.099

Gender (male) n, %

7 (70)

7 (70)

5 (83)

4 (67)

0.771

Dyspnea (%)e

n.a

n.a

4 (67%)

0 (0)

0.014

Symptomtic PAD

n.a

n.a

2 (33%)

0 (0)

 

Hypertension n, (%)

n.a

n.a

6 (100)

5 (83)

0.296

Hypercholesterolemia n, (%)

n.a

n.a

4 (67)

3 (50)

0.558

Active Smoking n, (%)

n.a

n.a

4 (67)

3 (50)

0.557

Family for CAD n, (%)

n.a

n.a

1 (17)

1 (17)

NA

Diabetes n (%)

n.a

n.a

2 (33)

0 (0)

0.455

LVEDVI (ml/m2)

87 ± 14

84 ± 10

79 ± 16

95 ± 16

0.247

LVESVI (ml/m2)

33 ± 7

33 ± 5

44 ± 26

52 ± 17

0.064

LVEF (%)d

63 ± 6

61 ± 12

58 ± 10

46 ± 11

0.002

LVMI (g/m2)b

60 ± 11

61 ± 17

85 ± 11

73 ± 16

0.009

LVM/LVEDVc, b

0.70 ± 11

0.72 ± 0,17

1.10 ± 0.15

0.77 ± 0.14

< 0.001

Global Longitudinal Strain (%)b

−22.78

−21.52

−16.43

−17.07

0.015

Ischemic Scar n, (%)f

n.a

n.a

n.a

6 (100)

n.a

Ischemic Scar Extent (% LV mass) f

n.a

n.a

n.a

8.4 ± 2.9

n.a.

Native T1 septum (ms) a

1000 ± 19

989 ± 27

1028 ± 31

1029 ± 44

0.029

Native T1 blood (ms)

1568 ± 85

1601 ± 110

1607 ± 101

1474 ± 257

0.317

T2 septum (ms)

43.8 ± 1.4

45.3 ± 1.8

46.2 ± 1.0

44.7 ± 3.0

0.099

Hct

0.43 ± 0.04

0.043 ± 0.06

0.40 ± 0.06

0.43 ± 0.04

0.726

ECV septumb

n.a.

0.244 ± 0.037

0.304 ± 0.0159

0.270 ± 0.017

0.003

IVV septum

0.135 ± 0.018

n.a.

0.155 ± 0.033

0.146 ± 0.038

0.413

Interstitial Space

n.a

n.a

0.149 ± 0.033

0.124 ± 0.044

0.281

  1. aBonferroni post-hoc analysis with p < 0.05 between post-MI and HFpEF versus the controls; bBonferroni post-hoc analysis with p < 0.05 between HFpEF versus the controls; cBonferroni post-hoc analysis with p < 0.05 between HFpEF versus post-MI patients; dBonferroni post-hoc analysis with p < 0.05 between post-MI patients versus controls; 1 patient in the HFpEF group with EF < 50% (= 48%). epatients were limited by peripheral arterial disease; fScar on late gadolinium enhancement. Hct: hematocrit; PAD: peripheral arterial disease